In This Section

Program

Notes: 

  • All session times for the AACR Virtual Meeting: Advances in Malignant Lymphoma: Maximizing the Basic-Translational Interface for Clinical Application are U.S. Eastern Daylight Time (EDT).
  • Poster presentations will be available throughout the meeting as an on-demand session beginning at 10 a.m. EDT on Monday, August 17. View the abstract titles and presenters of the accepted abstracts.

Monday, August 17, 2020

Tuesday, August 18, 2020

Wednesday, August 19, 2020

Monday, August 17, 2020

Welcome and Opening Keynote Address
10:30–11:15 a.m.

Welcome and Keynote Introduction
Ari M. Melnick, Weill Cornell Medical College, New York, New York

Rogue clones of self-reactive B cells with lymphoma driver mutations: A view of lymphoma precursors 
Christopher Goodnow, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia

Discussion / Q&A

Break
11:15–11:30 a.m.
Session 1: Teaching T-Cells New Tricks: Why Immunotherapy Fails in Lymphoma and How Do We Fix It?
Moderator: Helen E. Heslop, Baylor College of Medicine, Houston, Texas
11:30 a.m.–1:05 p.m.

Moderator Introduction
Helen E. Heslop

The bad guys of follicular lymphoma microenvironment: Putative impact on therapy failure?
Karin Tarte, Université de Rennes, Rennes, France

Immune exhaustion and suppression in lymphoma
Stephen M. Ansell, Mayo Clinic College of Medicine, Rochester, Minnesota

Optimizing immunostimulatory antibodies for cancer immunotherapy
Mark Cragg, University of Southampton, Southampton, United Kingdom

The immune cell microenvironment of classical Hodgkin lymphoma by single-cell analysis
Christian Steidl, BC Cancer, Vancouver, BC, Canada

Discussion / Q&A

Break
1:05–1:20 p.m.
Session 2: WHO vs. How? Changing Paradigms in Lymphoma Classification
Moderator: Georg Lenz, University of Münster, Münster, Germany
1:20–2:55 p.m.

Moderator Introduction
Georg Lenz

Molecular classification of T-cell lymphomas
Keisuke Kataoka, National Cancer Center, Japan, Tokyo, Japan

The role of gene expression in the classification of aggressive B-cell lymphoma
David W. Scott, BC Cancer, Vancouver, BC, Canada

Molecular classification of diffuse large B-cell lymphoma
Bjoern Chapuy, University of Göttingen, Göttingen, Germany

Microenvironmental signatures reveal biological and clinical subtypes of diffuse large B-cell lymphoma
Leandro C. Cerchietti, Weill Cornell Medical College, New York, New York

Discussion / Q&A

Break
2:55–3:10 p.m.
Session 3: Towards a Better Understanding of Adolescent Young Adult Lymphoma
Moderator: Sonali M. Smith, University of Chicago, Chicago, Illinois
3:10–4:20 p.m.

Moderator Introduction
Sonali M. Smith

AYA lymphomas: Bridging the divide
Kara Kelly, Roswell Park Comprehensive Cancer Center, Buffalo, New York

Genomics of common AYA lymphomas: Hodgkin lymphoma and primary mediastinal B-cell lymphoma
Lisa G. Giulino-Roth, Weill Cornell Medical College, New York, New York

Unique features of pediatric-type follicular lymphoma
Abner Louissaint, Massachusetts General Hospital, Boston, Massachusetts

Discussion / Q&A

Session 4: How Aberrant Metabolism Fuels Lymphoma
Moderator: Francesco Bertoni, Institute of Oncology Research, Bellinzona, Switzerland
3:10–4:05 p.m.

Moderator Introduction
Francesco Bertoni

Oncogenic Rag GTPase signaling links cellular nutrients with FL microenvironment
Alejo Efeyan, Spanish National Cancer Research Center, CNIO, Madrid, Spain

Metabolic control of lymphomagenesis
Andrew Michael Intlekofer, Memorial Sloan Kettering Cancer Center, New York, New York

Discussion / Q&A

Tuesday, August 18, 2020

Session 5: New CARs and Fine-Tuning Patient Selection for Therapy
Moderator: Renier J. Brentjens, Memorial Sloan Kettering Cancer Center, New York, New York
10–11:20 a.m.

Moderator Introduction
Renier J. Brentjens

CARs and armored CARs: Improving CAR T-cell therapy for cancer
Renier J. Brentjens

CAR T cells for T-cell lymphoma
Maksim Mamonkin, Baylor College of Medicine, Houston, Texas

Determinants of CAR-T outcomes: Host, tumor, and product
Sattva S. Neelapu, The University of Texas MD Anderson Cancer Center, Houston, Texas

Discussion / Q&A

Break
11:20–11:50 a.m.
Session 6: Biology-Based Clinical Trials: A Myth or Hope for Reality?
Moderator: John F. Seymour, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
11:50 a.m.–1:25 p.m.

Moderator Introduction
John F. Seymour

Can we hope for success in biologically stratified DLBCL studies?
Andrew John Davies, University of Southampton School of Medicine, Southampton, United Kingdom

Why good trials fail: Impact of biomarker requirement on the selection bias of study patients
Grzegorz S. Nowakowski, Mayo Clinic College of Medicine and Science, Rochester, Minnesota

Biomarker informed studies in peripheral T-cell lymphoma
Steven M. Horwitz, Memorial Sloan Kettering Cancer Center, New York, New York

Precision treatment of lymphoma using genomics
Louis M. Staudt, National Cancer Institute, Bethesda, Maryland

Discussion / Q&A

Break
1:25–1:40 p.m.
Session 7: Hacking the Lymphoma Epigenome to Create Better Therapies
Moderator: Ari M. Melnick, Weill Cornell Medical College, New York, New York
1:40–3:15 p.m.

Moderator Introduction
Ari M. Melnick

The role of EZH2 gain-of-function mutations in lymphoma
Wendy Béguelin, Weill Cornell Medical College, New York, New York

Cooperative epigenetic interactions in normal and transformed germinal center B cells
Laura Pasqualucci, New York Presbyterian Hospital Herbert Irving Comprehensive Cancer Center, New York, New York

CREBBP: Not all mutations are created equal
Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, Texas

What do the results from the trials tell us?
Peter W.M. Johnson, University of Southampton, Southampton, United Kingdom

Discussion / Q&A

Break
3:15–3:30 p.m.
Session 8: Cancer Health Disparities in Lymphoma: How Do We Improve Outcomes?
Moderator: Christopher R. Flowers, The University of Texas MD Anderson Cancer Center, Houston, Texas
3:30–4:40 p.m.

Moderator Introduction
Christopher R. Flowers

Risk disparities in lymphoid cancers: What we know and what we don’t
Wendy Cozen, USC Norris Comprehensive Cancer Center, Los Angeles, California

Disparities in late effects incidence among adolescent and young survivors of lymphoma
Theresa H. M. Keegan, University of California Davis, Sacramento, California

Genome-estimated African ancestry is associated with distinct tumor mutations and poorer survival in patients with diffuse large B-cell lymphoma
Christopher R. Flowers

Discussion / Q&A

Session 9: Hitting Back at MYC/BCL2 Lymphomas
Moderator: David M. Weinstock, Dana-Farber Cancer Institute, Boston, Massachusetts
3:30–4:40 p.m.

Moderator Introduction
David M. Weinstock

Targeting MYC deregulation in cancer
Dinis Calado, The Francis Crick Institute, London, United Kingdom

Modeling and targeting double-hit lymphoma
Bruno Amati, European Institute of Oncology, Milan, Italy

Targeting BCL-2 with venetoclax
Jennifer R. Brown, Dana-Farber Cancer Institute, Boston, Massachusetts

Discussion / Q&A

Wednesday, August 19, 2020

Session 10: Dissecting Lymphoma Cell by Cell: A Dynamic Tale
Moderator: Kojo Elenitoba-Johnson, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania
10–11:35 a.m.

Moderator Introduction
Kojo Elenitoba-Johnson

Single-cell delineation of clonal variation and cellular tumor microenvironmental interactions in follicular lymphoma
Hanlee P. Ji, Stanford University, Stanford, California

Pathology from the atomic scale on up
Garry P. Nolan, Stanford Hospital, Stanford, California

Follicular lymphoma dynamics through single-cell analysis
Bertrand Nadel, Centre d’Immunologie de Marseille-Luminy, Marseille, France

Characterizing the tumor ecosystem in follicular lymphoma by CyTOF
Andrew P. Weng, BC Cancer, Vancouver, BC, Canada

Discussion / Q&A

Break
11:35–11:50 a.m.
Session 11: Can We Find and Destroy Lymphoma Precursor Cells?
Moderator: Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, Texas
11:50 a.m.–1:25 p.m.

Moderator Introduction
Michael R. Green

Tracking precursor stages of follicular lymphoma development
Sandrine Roulland, Centre d’Immunologie de Marseille-Luminy, Marseille, France

Defining lymphoma reservoirs: Clues from the genomics
Jessica Okosun, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

Investigating malignant transformation in Waldenstrom’s Macroglobulinemia
Zachary R. Hunter, Dana-Farber Cancer Institute, Boston, Massachusetts

Defining precursors in low-grade lymphomas that seed second lymphomas
David M. Weinstock, Dana-Farber Cancer Institute, Boston, Massachusetts

Discussion / Q&A

Break
1:25–1:40 p.m.
Session 12: Using Liquid Biopsies for Real-Time Monitoring of Lymphoma Biology and Clinical Decision-Making
Moderator: David W. Scott, BC Cancer, Vancouver, BC, Canada
1:40–3:15 p.m.

Moderator Introduction
David W. Scott

Approaches for personalized medicine in lymphoma through liquid biopsies
David M. Kurtz, Stanford University, Stanford, California

Detecting and quantifying mutations associated with treatment resistance in aggressive lymphomas using ctDNA
Ryan D. Morin, Simon Fraser University, Burnaby, BC, Canada

Qualification and quantification of lymphoma under therapy by ctDNA analysis
Davide Rossi, Institute of Oncology Research, Bellinzona, Switzerland

ctDNA in indolent lymphoid cancers treated with targeted therapies
Constantine S. Tam, St. Vincent’s Hospital, East Melbourne, Australia

Discussion / Q&A

Break
3:15–3:30 p.m.
Session 13: Preclinical Models: How to Best Predict Therapeutic Response
Moderator: Teresa Palomero, Columbia University, New York, New York
3:30–4:55 p.m.

Moderator Introduction
Teresa Palomero

Developing preclinical models for peripheral T-cell lymphomas
Teresa Palomero

Molecular and genetic profiling in canine lymphoma unravels targets for the human counterpart
Luca Aresu, University of Turin, Turin, Italy

Patient-derived tumor xenograft of human lymphomas
Giorgio Inghirami, Weill Cornell Medicine, New York, New York

Lymphoma organoids to study cooperative signaling and therapeutic resistance in human DLBCLs
Ankur Singh, Georgia Institute of Technology, Atlanta, Georgia

Discussion / Q&A

Session 14: Understanding and Targeting Aberrant Receptor Signaling in Lymphoma
Moderator: Louis M. Staudt, National Cancer Institute, Bethesda, Maryland
3:30–4:40 p.m.

Moderator Introduction
Louis M. Staudt

MALT1 targeting for B-cell lymphomas
Lorena Fontan, Weill Cornell Medical College, New York, New York

Tracking MYC-lymphoma evolution in vivo: Role of the B-cell receptor
Stefano Casola, The FIRC Institute of Molecular Oncology (IFOM), Milan, Italy

B-cell receptor– and co-receptor–driven metabolism reprogramming
Benjamin Gewurz, Brigham & Women’s Hospital, Boston, Massachusetts

Discussion / Q&A

Break
4:55–5:10 p.m.
Keynote Address and Closing Remarks
5:10–6 p.m.

Keynote Introduction
Ari M. Melnick, Weill Cornell Medical College, New York, New York

Cellular and molecular control of germinal center B-cell selection
Gabriel Victora, The Rockefeller University, New York, New York

Discussion / Q&A

Closing Remarks